PBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prestige Consumer Healthcare Inc (PBH) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks immediate positive catalysts, has declining financial performance, and no significant trading signals. While the acquisition of the Breathe Right brand could be a long-term positive, the current technical and sentiment indicators suggest waiting for a clearer entry point.
The MACD is negative and contracting, RSI is neutral at 33.302, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 60.2), with resistance at R1: 63.627. Overall, the technical indicators suggest a bearish trend.
The acquisition of the Breathe Right brand and other OTC health products for $1.045 billion, expected to close in fiscal 2027, could enhance competitiveness in the health consumer goods sector.
Declining financial performance in Q3 2026, with revenue down 2.37% YoY, net income down 23.49% YoY, and EPS down 20.49% YoY. Insider selling has increased by 291.04% over the last month, and analysts have lowered price targets, citing weak U.S. OTC trends and limited recovery in eye care.
In Q3 2026, revenue dropped to $283.4M (-2.37% YoY), net income dropped to $46.7M (-23.49% YoY), EPS dropped to $0.97 (-20.49% YoY), and gross margin slightly decreased to 53.7% (-0.13% YoY).
Canaccord maintains a Buy rating but lowered the price target to $86 from $88. Jefferies maintains a Hold rating and lowered the price target to $66 from $70, citing range-bound shares until a catalyst like M&A emerges.
